We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
United Therapeutics (UTHR) Moves 12.6% Higher: Will This Strength Last?
Read MoreHide Full Article
United Therapeutics (UTHR - Free Report) shares ended the last trading session 12.5% higher at $541.89. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 6.1% loss over the past four weeks.
United Therapeutics’ share price increased after a Delaware court ruled that Liquidia’s Yutrepia infringes two claims of UTHR’s patent covering inhaled treprostinil for PH-ILD. The ruling could lead to restrictions on Yutrepia’s PH-ILD use, potentially reducing competition for United Therapeutics’ Tyvaso and Tyvaso DPI products. The company could further benefit from potential monetary damages related to Liquidia’s past infringement, although the final remedies remain pending.
This drugmaker is expected to post quarterly earnings of $6.38 per share in its upcoming report, which represents a year-over-year change of -10.9%. Revenues are expected to be $792.64 million, down 0.9% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For United Therapeutics, the consensus EPS estimate for the quarter has been revised 1.4% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on UTHR going forward to see if this recent jump can turn into more strength down the road.
United Therapeutics is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, Stevanato Group (STVN - Free Report) , finished the last trading session 1% lower at $20.98. STVN has returned 2.4% over the past month.
For Stevanato, the consensus EPS estimate for the upcoming report has changed +1.1% over the past month to $0.18. This represents a change of +12.5% from what the company reported a year ago. Stevanato currently has a Zacks Rank of #4 (Sell).
View the Zacks #1 Rank List
Image: Bigstock
United Therapeutics (UTHR) Moves 12.6% Higher: Will This Strength Last?
United Therapeutics (UTHR - Free Report) shares ended the last trading session 12.5% higher at $541.89. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 6.1% loss over the past four weeks.
United Therapeutics’ share price increased after a Delaware court ruled that Liquidia’s Yutrepia infringes two claims of UTHR’s patent covering inhaled treprostinil for PH-ILD. The ruling could lead to restrictions on Yutrepia’s PH-ILD use, potentially reducing competition for United Therapeutics’ Tyvaso and Tyvaso DPI products. The company could further benefit from potential monetary damages related to Liquidia’s past infringement, although the final remedies remain pending.
This drugmaker is expected to post quarterly earnings of $6.38 per share in its upcoming report, which represents a year-over-year change of -10.9%. Revenues are expected to be $792.64 million, down 0.9% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For United Therapeutics, the consensus EPS estimate for the quarter has been revised 1.4% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on UTHR going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
United Therapeutics is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, Stevanato Group (STVN - Free Report) , finished the last trading session 1% lower at $20.98. STVN has returned 2.4% over the past month.
For Stevanato, the consensus EPS estimate for the upcoming report has changed +1.1% over the past month to $0.18. This represents a change of +12.5% from what the company reported a year ago. Stevanato currently has a Zacks Rank of #4 (Sell).